Indivior Declares $8.13 Special Dividend Tied to Supernus Merger

Indivior Pharmaceuticals’ $8.13-per-share special cash dividend went ex-dividend on November 3, 2026, and is scheduled for payment on November 6, 2026. The distribution is tied to the company’s completed merger with Supernus Pharmaceuticals and does not establish a recurring dividend.

Why the dividend changed

Indivior explicitly described the payment as a special cash dividend contingent on completion of its merger with Supernus. The transaction closed on November 2, and the combined company began operating as Supernus, Inc., with its shares trading under the SUPN ticker from November 3. That sequence makes the payment a merger-related distribution to legacy Indivior holders, not the start of a routine annual payout. Indivior’s dividend declaration

The merger agreement called for Indivior shareholders to receive a one-time distribution immediately before closing. Supernus shareholders were not entitled to the payment on shares received as merger consideration. The companies said the dividend would be financed with a term loan and cash held by the combined business, shifting part of the transaction value directly to legacy Indivior shareholders while adding a financing obligation to the post-merger company. Supernus-Indivior merger announcement

Indivior entered the transaction after a stronger operating period. Third-quarter net revenue was $356 million, including $267 million from SUBLOCADE, while GAAP net income was $137 million and adjusted EBITDA was $211 million. Management said the standalone business remained on track to meet its full-year guidance, but that guidance ceased to apply after the merger closed. Indivior’s third-quarter results

Dividend track record

The recent payment record contains the $8.13 distribution with an ex-dividend date of November 3, 2026. There is no completed full-year payment pattern, and the dividend-growth streak stands at 0 years. The record therefore does not support treating Indivior as an established dividend grower.

The annual dividend figure associated with this event is $8.13 per share, but the company’s description is more important than the annual frequency label. Indivior called the payment special and connected it directly to the merger. The declaration did not commit the combined company to another $8.13 payment or establish a schedule for future distributions.

Is the dividend covered?

The stated earnings payout ratio is 0%. That conventional ratio is not a meaningful measure of coverage for this event because the $8.13 payment is a transaction-funded special distribution rather than a recurring dividend drawn from a stated share of annual earnings. The 0% figure consequently does not mean the cash payment has no financial cost.

Indivior’s latest quarterly filing said the special dividend would be funded through a senior secured term loan and cash on hand at the combined company. The filing also said existing liquidity, operating cash generation and debt were expected to meet anticipated needs for at least the following 12 months. That statement addresses near-term liquidity, but it is not a commitment to ongoing dividends. Indivior’s third-quarter Form 10-Q

Yield and valuation

At a share price of $36.28, the $8.13 annual dividend figure produces a 22.41% forward yield. That compares with a 1.63% median forward yield for the Healthcare sector. Indivior’s market value is $4.3 billion.

The unusually high yield reflects the size of a one-time merger distribution relative to the pre-distribution share price. It is not evidence that the combined company has adopted a recurring yield of 22.41%. Comparing it directly with regular Healthcare dividends therefore overstates the continuing income attached to the shares.

What to watch

The immediate item is payment of the $8.13 dividend on November 6, 2026. After payment, the relevant disclosures will come from Supernus under the SUPN ticker rather than from Indivior as a standalone company.

Future reports will show the combined company’s post-dividend cash position, term-loan obligations, merger integration costs and capital-return policy. Indivior’s former standalone guidance no longer applies, and the special-dividend declaration did not establish a date or amount for another distribution.